A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences
暂无分享,去创建一个
A. De Vita | F. Recine | L. Gurrieri | R. Casadei | T. Ibrahim | L. Mercatali | C. Calabrese | C. Liverani | Alberto Bongiovanni | F. Pieri | C. Spadazzi | G. Miserocchi | C. Cocchi | S. Vanni | V. Fausti
[1] A. De Vita,et al. Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas , 2021, International journal of molecular sciences.
[2] G. Hu,et al. Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone , 2021, Cell Death & Disease.
[3] B. Morland,et al. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. , 2021, The Lancet Oncology.
[4] T. Kondo,et al. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone , 2021, Human Cell.
[5] H. Sakale,et al. Mammoth Giant Cell Tumor of the First Metacarpal: A Case Report and Management Trends , 2021, Cureus.
[6] A. De Vita,et al. The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient‐derived primary culture case series in tridimensional and zebrafish models , 2021, Journal of experimental & clinical cancer research : CR.
[7] Dil V. Patel,et al. Giant cell tumor of the thoracic spine causing acute paraplegia-a case report. , 2021, Journal of spine surgery.
[8] A. De Vita,et al. Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas , 2021, Cancer biology & medicine.
[9] N. Ramírez,et al. Giant cell tumor of bone at the proximal epiphysis of humerus in a skeletally immature patient: A case report , 2020, International journal of surgery case reports.
[10] A. Puri,et al. The current standing on the use of denosumab in giant cell tumour of the bone , 2020, Journal of orthopaedic surgery.
[11] M. Bianchi,et al. The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration , 2020, Frontiers in Immunology.
[12] J. Yayan. Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis , 2019, Cancer control : journal of the Moffitt Cancer Center.
[13] Zhonglin Hao,et al. Lenvatinib in Management of Solid Tumors. , 2019, The oncologist.
[14] H. Gelderblom,et al. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone , 2019, Current opinion in oncology.
[15] K. Horiuchi,et al. Desmoplastic fibroma of bone arising in the cortex of the proximal femur. , 2021, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.
[16] D. Campanacci,et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] D. Amadori,et al. Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma. , 2018, Journal of visualized experiments : JoVE.
[18] Hailin Zhao,et al. The role of osteopontin in the progression of solid organ tumour , 2018, Cell Death & Disease.
[19] K. Nakano,et al. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas , 2018, International journal of molecular sciences.
[20] D. Amadori,et al. Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition , 2017, International journal of molecular sciences.
[21] G. Farfalli,et al. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls. , 2017, Human pathology.
[22] R. Mohankumar,et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. , 2016, European journal of cancer.
[23] D. Cohen,et al. Desmoplastic Fibroma of the Mandible: A Series of Three Cases and Review of Literature , 2015, Head and Neck Pathology.
[24] D. Amadori,et al. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. , 2014, Bone.
[25] R. Grimer,et al. Desmoplastic fibroma of bone: A rare bone tumour , 2014, Journal of bone oncology.
[26] H. Gelderblom,et al. The clinical approach toward giant cell tumor of bone. , 2014, The oncologist.
[27] Kang Z. Liu,et al. Protein kinase C regulates FLT1 abundance and stimulates its cleavage in vascular endothelial cells with the release of a soluble PlGF/VEGF antagonist. , 2013, Experimental cell research.
[28] David M. Thomas,et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. , 2013, The Lancet. Oncology.
[29] P. Raab,et al. Desmoplastic Fibroma: A Case Report with Three Years of Clinical and Radiographic Observation and Review of the Literature , 2013, The open orthopaedics journal.
[30] H. Knowles,et al. VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology , 2012, Laboratory Investigation.
[31] J. Wanders,et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours , 2012, British Journal of Cancer.
[32] David M. Thomas,et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. , 2010, The Lancet. Oncology.
[33] C. Errani,et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. , 2010, Cancer treatment reviews.
[34] P. Kostenuik,et al. Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] M. Balke,et al. Giant cell tumor of bone: treatment and outcome of 214 cases , 2008, Journal of Cancer Research and Clinical Oncology.
[36] M. Agarwal,et al. Giant Cell Tumor of Bone in Children and Adolescents , 2007, Journal of pediatric orthopedics.
[37] H. Yoshida,et al. Giant cell tumor of bone , 2004, Virchows Archiv A.
[38] S. Kumta,et al. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. , 2003, Life sciences.
[39] P. Julka,et al. Radiotherapy for Desmoplastic Fibroma of Bone: A Case Report , 2003, Journal of orthopaedic surgery.
[40] P. Picci,et al. Prognostic relevance of C‐myc gene expression in giant‐cell tumor of bone , 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[41] M. Laniado,et al. Desmoplastic fibroma of the bone: A report of two patients, review of the literature, and therapeutic implications , 1996, Cancer.
[42] N. Sanfilippo,et al. Desmoplastic fibroma: a role for radiotherapy? , 1995, Southern medical journal.
[43] W. Sanger,et al. Cytogenetic findings and biologic behavior of giant cell tumors of bone , 1990, Cancer.
[44] W. Enneking. A system of staging musculoskeletal neoplasms. , 1986, Clinical orthopaedics and related research.
[45] W. Ober. Tumors and Tumorous Conditions of the Bones and Joints , 1959, The Yale Journal of Biology and Medicine.
[46] H. Jaffe. Giant-cell tumour (osteoclastoma) of bone: its pathologic delimitation and the inherent clinical implications. , 1953, Annals of the Royal College of Surgeons of England.
[47] Yon E.udolpii. On Tumours , 1864, The British and Foreign Medico-Chirurgical Review.